April 17, 2006

Lilly drug cuts breast cancer risk, fewer side-effects

WASHINGTON (Reuters) - Evista, Eli Lilly and Co's
osteoporosis drug, works just as well as the older drug
tamoxifen in reducing the risk of breast cancer in high-risk
women, and without some of the dangerous side-effects,
researchers said on Monday.

The results of the 19,000-woman Study of Tamoxifen and
Raloxifene (STAR) trial show that Evista, known generically as
raloxifene, is less likely to cause blood clots and uterine
cancer, yet like tamoxifen lowers the risk of breast cancer by
50 percent.

Women have long been prescribed tamoxifen, sold as a
generic and by AstraZeneca Plc under the brand name Nolvadex,
both to treat and prevent breast cancer. Lilly said it would
seek U.S. Food and Drug Administration approval to market
Evista both for osteoporosis and to prevent breast cancer.